Cash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech (LEGN) believes will provide financial runway into the second quarter of fiscal year 2026
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Corporation (LEGN) Q4 Earnings Cheat Sheet
- Positive Developments in Carvykti Therapy Propel Legend Biotech to ‘Buy’ Rating
- Legend Biotech price target lowered to $84.28 from $92.97 at Goldman Sachs
- Legend Biotech Reports Q4 CARVYKTI® Sales
- Legend Biotech Showcases CAR-T Therapy Success at J.P. Morgan Healthcare Conference